BiotechTube

ALPS12 + obinutuzumab

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive Stage Small Cell Lung Cancer

Conditions

Extensive Stage Small Cell Lung Cancer

Trial Timeline

Oct 8, 2025 → Sep 30, 2028

NCT ID
NCT07107490

About ALPS12 + obinutuzumab

ALPS12 + obinutuzumab is a phase 1 stage product being developed by Chugai Pharmaceutical for Extensive Stage Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07107490. Target conditions include Extensive Stage Small Cell Lung Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT07107490Phase 1Recruiting

Competing Products

20 competing products in Extensive Stage Small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Atezolizumab + CarboplatinDaiichi SankyoPhase 1/2
41
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
LY2510924 + Carboplatin + EtoposideEli LillyPhase 2
52
SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3
77
Epirubicin plus SHR1210Jiangsu Hengrui MedicinePhase 2
52
Durvalumab plus chemotherapyAstraZenecaPhase 3
77
Durvalumab + Tremelimumab + Olaparib Pill + TremelimumabAstraZenecaPhase 1
33
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Etoposide + CarboplatinAstraZenecaPhase 3
77
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Cisplatin + Carboplatin + Etoposide + Durvalumab + CeralasertibAstraZenecaPhase 2
52
Carboplatin + Cisplatin + Durvalumab + EtoposideAstraZenecaPhase 2
52
Carboplatin + Durvalumab + Etoposide + OlaparibAstraZenecaPhase 1/2
41
Durvalumab + Tremelimumab + Carboplatin + Cisplatin + EtoposideAstraZenecaPhase 3
77
Bomedemstat + AtezolizumabMerckPhase 1/2
41

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77